Sonnet BioTherapeutics (SONN) 8-K Sonnet BioTherapeutics Holdings Announces Merger Closing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Sonnet BioTherapeutics, Inc.:

We consent to the incorporation by reference in the registration statements (No. 333-214319 and No. 333-230857) on Form S-1, registration statements (No. 333-226107, No. 333-220336, and No. 333-237354) on Form S-3, and registration statement (No. 333-193742) on Form S-8 of Chanticleer Holdings, Inc. of our report dated November 27, 2019, with respect to the balance sheets of Sonnet BioTherapeutics, Inc. as of September 30, 2019 and 2018, the related statements of operations, stockholders’ deficit, and cash flows for the years then ended, and the related notes, which report appears in the Form 8-K of Chanticleer Holdings, Inc. dated April 2, 2020.

Our report dated November 27, 2019 contains an explanatory paragraph that states that Sonnet BioTherapeutics, Inc. has incurred recurring losses and negative cash flows from operations from inception, has a stockholders’ deficit of $2,845,487 as of September 30, 2019, and will require substantial additional financing to continue to fund its research and development activities that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ KPMG LLP

Philadelphia, Pennsylvania

April 2, 2020